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Abstract
Background To gain insight into factors that might affect results 
of future case-control studies, we performed an analysis of 
children w ith sepsis and purpura admitted to the paediatric 
intensive care unit (PICU) of Erasmus MC-Sophia Children's 
Hospital (Rotterdam, The Netherlands).
Methods Between 1988 and 2006, all 287 children 
consecutively admitted with sepsis and purpura were included 
in various sepsis studies. Data regarding age, gender, ethnicity, 
serogroup of Neisseria meningitidis, severity, therapy, and 
survival were collected prospectively. These data were pooled 
into one database and analyzed retrospectively.
Results The case fatality rate (CFR) from sepsis and purpura 
was 15.7%. During the study period, survival improved 
significantly. Younger age was significantly associated with 
more severe disease and a higher CFR. Children under the 
median age of 3 .0 years had an increased risk of case fatality
(odds ratio 4.3, 95%  confidence interval 2.1 to 9.2; p  <  0.001). 
Gender was not associated w ith CFR. However, males did have 
higher Paediatric Risk of Mortality scores, fewer PICU-free days, 
and more presence of shock. The course of sepsis and purpura 
was not related to ethnic origin. A causative organism was 
isolated in 84.3%  of cases. N. m eningitid is was the major 
organism (97.5%). Although N. m eningitidis serogroup B was 
observed more often in younger children, serogroups were not 
associated with severity or survival. During the study period, the 
use of inotropic agents and corticosteroids changed 
substantially (less dopamine and more dobutamine, 
norepinephrine, and corticosteroids).
Conclusion Age and gender are determinants of severity of 
paediatric sepsis and purpura. Survival rates have improved 
during the last tw o decades.
Introduction
Sepsis and purpura in children is a clinically d istinct disease 
entity caused by high concentrations of m icrobes and their 
products. S ince the introduction of a vaccine against Haem o­
ph ilus  influenzae  type b, more than 90%  of the cases of sep­
sis and purpura in the W estern world have been caused by 
Neisseria m ening itid is  [1-3]. The resulting disease entity is 
referred to as m eningococcal sepsis.
M eningococcal sepsis in children develops when the initial 
host response to the infection becom es inappropriately ampli­
fied and dysregulated. C linically, the onset is often insidious. 
A fter the development of the first petechiae, the patient rapidly 
deteriorates and may subsequently develop shock, dissem i­
nated intravascular coagulation (DIC), and ultimately organ 
failure. The severity of these symptoms requires immediate 
therapy [4,5]. Despite recent advances in therapy, the case
CFR =  case fatality rate; CI =  confidence interval; CRP =  C-reactive protein; DIC =  disseminated intravascular coagulation; PDR =  predicted death 
rate; PICU =  paediatric intensive care unit; PRISM =  Paediatric Risk of Mortality; rs =  Spearman correlation coefficient.
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fatality rate (CFR) remains high and ranges from 4%  to 40%  
[1,6-8]. The incidence of disease is highest among young chil­
dren (0 to 4 years old) and adolescents [1-3]. In The Nether­
lands, m eningococcal sepsis occurs in 4.5 per 100,000 
inhabitants (2001). Due to the sudden increase in the inci­
dence of m eningococcal disease in 2001, a national vaccina­
tion campaign against serogroup C  m eningococci (2002) was 
implemented among children from 1 to 18 years of age [9,10].
In recent years, many studies have focused on the elucidation 
of the pathogenesis of sepsis. However, much about the ep i­
dem iology of sepsis in children is still unknown. In this paper, 
w e seek to describe the epidem iology of sepsis and purpura 
in children referred to the paediatric intensive care unit (PICU) 
of Erasmus M C-Sophia Children's Hospita l in Rotterdam, The 
Netherlands. The aim of this study was to analyze the variation 
in severity and survival of children w ith respect to age, gender, 
ethnicity, and serogroup of N. m eningitid is.
Materials and methods
The study was conducted in accordance w ith the Declaration 
of Helsinki. Permission for the study was obtained from the 
medical ethics com m ittee of Erasmus MC.
Participants
All children adm itted w ith sepsis and purpura (and/or 
petechiae) to the PICU of the Erasmus M C-Sophia Children's 
Hospital since 1988 were included. A  vast majority of the chil­
dren were previously included in Rotterdam-based sepsis
studies [11-16]. Data regarding the remaining children w ith 
sepsis and purpura were derived from PICU admission 
records. Informed consent was obtained from parents or legal 
guardians of all children who were included in this study. C h il­
dren were considered to have sepsis when they presented 
w ith tachycardia, tachypnea, and a body temperature of less 
than 36°C  or greater than 38 .5°C  (rectal) [17]. Prospective 
data on all children were collected at various time points in the 
course of the disease. Both  laboratory parameters and dis­
ease severity scoring systems, like Paediatric Risk of M ortality 
(PRISM) score and predicted death rate (PDR) based on the 
Rotterdam  score, were selected as markers of severity of d is ­
ease [18-20]. Additionally, presence of D IC and presence of 
shock were recorded as markers of severity [17 ,19,21]. The 
number of PICU-free days was determ ined on day 28 after 
admission using the date of admission and the date of d is­
charge. A  non-survivor had 0 PICU-free days. All laboratory 
parameters, obtained at baseline from an arterial b lood sam­
ple, were collected within 4 hours after admission to the PICU.
Ethnicity was determ ined by checking patient information, and 
if it was not specified, first and last names were checked and 
ethnicity was determ ined by means of the com bined name 
method [22]. Ethnicity was categorized into Dutch Caucasian, 
Turkish, Moroccan, Hindustani, African descent, and other. 
Serogrouping of N. m eningitid is  isolates was performed at the 
Netherlands Reference Laboratory for Bacterial M eningitis 
Amsterdam using immunodiffusion w ith polyclonal antisera
[23].
F igu re  1
Distribution of age at admission in children with sepsis and purpura. The children are subdivided according to causative organism. N. meningitidis, 
Neisseria meningitidis. Not further defined (n.f.d.).
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Table 1 F igure  2
C om parison  o f d isease  cha racte ris tics  be tw een non-surv ivors  
and su rv ivors
Survivors3 Non-survivorsa
Total number of children (%) 242 45
(84.3) (15.7)
Male-to-female ratio 1.1 1.7
Number of children with DIC (%) 1 74b 32b
Neisseria meningitidis serogroup
(75) (97)
B (%) 147 (74.2) 28 (73.7)
C (%) 37 (18.7) 7 (18.4)
PRISM score 1 4c 23c
(1 t0 37) (8 to 44)
Predicted death rate (%)d 3.1c 87.4c
(0 to 100) (1.1 to 100.0)
Base excess (mmol/L) -7c -13c
(-23 to 4.4) (-28 to 0.6)
Lactate (mmol/L) 3.7c 6.6c
Geometric mean, 95% CI 3.4 to 4.3 5.8 to 7.4
C-reactive protein (mg/L) 106c 53c
(10 to 334) (6 to 226)
Fibrinogen (g/L) 2.8c 0.9c
(0.3 to 6.8) (0.2 to 5.4)
Platelet count (x103/^L) 126c 47c
(15 to 475) (13 to 202)
Leukocytes (x103/^L) 10.6c 4.7c
Geometric mean, 95% CI 9.5 to 11.9 3.7 to 6.0
Glucose (mmol/L) 6.3c 4.3c
Geometric mean, 95% CI 5.9 to 6.8 3.6 to 5.3
aResults represent median (min-max) unless stated otherwise. bp <  
0.01 .cp <  0.001. dPredicted death rate was based on the Rotterdam 
score. CI, confidence interval; DIC, disseminated intravascular 
coagulation; PRISM, Paediatric Risk of Mortality.
Statistical analyses
Retrospectively, severity and survival of children w ith sepsis 
and purpura w ith respect to age, gender, causative organism, 
and ethnicity were analyzed by means of SPSS 11.01 (SPSS 
Inc., Chicago, IL, USA) C linical and laboratory parameters 
were included in the analysis only if they were determ ined in at 
least 90%  of all children.
Mann-W hitney U test, S tudent t test, chi-square test, and 
Spearman correlation (rs) were used when appropriate. W hen 
necessary, variables were log-transformed to obtain an
-C ase  F a ta lity  Rate (CFR) --------Linear (Case F a ta lity  Rate (CFR)}
Case fatality rate (CFR) and CFR trend line during the study period.
approximately normal distribution. For these variables, geo­
m etric mean values and the ir 95%  confidence intervals (CIs) 
are depicted in the text and tables. P  values of less than or 
equal to 0 .05 were considered statistically significant.
Results
Between August 1988 and June 2006, 287 children w ith sep­
sis and purpura were adm itted to the PICU of the Erasmus 
M C-Sophia Children's Hospital. The overall CFR was 15.7%  
(45 children died). The median age at admission was 3.0 years 
(range 0.1 to 1 7.9 years) (Figure 1). O f the 287 children, 155 
(54% ) were male and 132 (46% ) were female. The male-to- 
female ratio was 1.2. The majority of the children were Dutch 
Caucasians (73.8% ). Laboratory parameters present at base­
line in more than 90%  of the children were base excess, lac­
tate, C-reactive protein (CRP), fibrinogen, platelet count, 
leukocytes, and glucose.
Survival
Severity of illness was significantly less in survivors when com ­
pared w ith non-survivors, both in disease severity scoring sys­
tems and laboratory parameters (Table 1). Survival was 
significantly correlated w ith year of admission (p < 0.05, rs 
0.128), indicating that survival has improved significantly dur­
ing the study period (Figure 2). G ender did not differ between 
survivors and non-survivors (p =  0.15). The vast majority of 
fatal cases died of refractory sep tic  shock (75.6% ).
Age
Age was significantly correlated w ith PRISM score (p <  0.001, 
rs -0.317), PDR (p <  0.001, rs -0.321), presence of D IC (p <  
0.001, rs -0.245), base excess (p <  0.001, rs 0.313), CRP (p 
<  0.05, rs 0.161), fibrinogen (p <  0.001, rs 0.301), leukocyte 
count (p <  0 .001, rs 0.284), throm bocyte count (p <  0.01, rs 
0.184), and glucose levels (p <  0.001, rs 0.296). This indi­
cates that younger children had higher PRISM scores, higher 
PDR, more presence of DIC, lower base excess, lower CRP,
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lower fibrinogen, lower leukocyte count, lower throm bocyte 
count, and lower glucose levels on admission. The median age 
of children was 3.0 years (range 0.1 to 17.9 years). Children 
3.0 years old or younger had a higher CFR (odds ratio 4.3, 
95%  CI 2.1 to 9.2; p  <  0 .001) (Figure 3).
Gender
The median age did not differ significantly between males (2.8 
years) and females (3.5 years) (p =  0.16). Male patients had 
significantly few er PICU-free days (p =  0.04) and higher 
PRISM scores (p =  0.02) than females. Shock was slightly 
more common in males than in females (89%  versus 80% ; p  
=  0.04). CFR and other markers of severity of disease did not 
differ between males and females. Because males had higher 
PRISM scores but no increased CFR, we analyzed the differ­
ent variables determ ining the PRISM score. O f these variables, 
only a trend for lower glucose levels in males com pared with 
females was observed (p =  0.06).
Ethnicity
The majority of the children were Dutch Caucasians (n =  211, 
73.5% ). O f the remaining 76 children, 12 were Turkish (4.2%), 
16 were Moroccan (5.6%), 3 were H industani (1.1%), 7 were 
of African descent (2.5%), 7 were designated other (2.5%), 
and in 31 children ethnicity could not be determ ined (10.8% ). 
No differences w ith respect to severity of disease or case 
fatality were found between the different ethnic groups.
Causative organism
A causative organism could be determ ined in 242 children 
(84.3% ), w ith N. m eningitid is  being the major causative 
organism (n =  236, 97.5% ) (Figure 4). O f these 236, 175
(74.2% ) were N. m ening itid is  serogroup B, 44 (18.6% ) were 
serogroup C, and in 17 (7.2% ) the serogroup was not de ter­
mined (Table 2). Streptococcus pneum oniae  was the 
causative organism in 3 children, Staphylococcus aureus in 1, 
and H. influenzae  in 2. O f the remaining 45 children, 43  had 
clinical features of m eningococcal sepsis [3].
For logistic reasons, the causative organism could not be 
determ ined in 2 children. No differences w ith respect to sur­
vival, disease severity scoring systems, and presence of shock 
were observed between N. m eningitid is  serogroups B and C. 
However, the median age of children w ith sepsis and purpura 
due to serogroup B was lower than that of the serogroup C- 
infected children (2.8 and 6.0 years, respectively; p  <  0 .001) 
(Table 3). The distribution of serogroup, serotype, and sero­
subtype of N. m ening itid is  in the positive cultures is depicted 
in Table 2.
Meningococcal C vaccination campaign and therapy
In 2001 and 2002, a sudden increase was noted in the inci­
dence of m eningococcal infection in The Netherlands. This 
was caused mainly by serogroup C  N. m eningitid is. The imple­
mentation of the m eningococcal C  vaccination campaign in 
July 2002  resulted in a sharp decline in the number of cases 
caused by serogroup C  (Figure 4). S ince 2003, there has not 
been a case of sepsis and purpura due to N. m eningitid is  
serogroup C  in our hospital. Parallel to this, the incidence of 
serogroup B has declined and is returning to the incidence 
level of before 1989. Before the national m eningococcal C  
vaccination, 248  children in our study population were adm it­
ted w ith sepsis and purpura; since the vaccination campaign, 
39  children have been admitted.
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Table 2
Inc idence o f se rog roup, sero type , and se rosub type  o f N e isse ria  m e n in g it id is
Serogroup Serotype Serosubtype Number Percentage
1 P1.4 4 1.8
P1.16 4 1.8
NT 3 1.4
Other 1 0.5
2A 3 1.4
4 P1.4 57 26
P1.6 3 1.4
P1.7 3 1.4
P1.9 4 1.8
P1.10 4 1.8
P1.15 5 2.3
NT 28 12.8
Other 13 5.9
NT P1.1 6 2.7
P1.4 8 3.7
NT 8 3.7
Other 4 1.8
Other 17 7.8
2A P1.2 12 5.5
P1.5 9 4.1
P1.7 1 0.5
NT 7 3.2
2B P1.1 1 0.5
P1.2 7 3.2
4 P1.4 3 1.4
NT 2 0.9
Other 2 0.9
NT, non-typable.
Remarkably, since the implementation of m eningococcal C  
vaccination, no deaths have occurred in children w ith sepsis 
and purpura adm itted to our PICU. The median age of the chil­
dren did not differ significantly before and after vaccination 
(3.2 and 2.5 years, respectively; p  =  0.23) (Table 4 ). G lucose 
levels were significantly lower in the patient group before the 
vaccination campaign compared w ith the patient group after 
(p <  0.05). Children adm itted before the vaccination campaign 
had significantly few er PICU-free days and more presence of 
DIC (both p  <  0.05). The PRISM score was not significantly 
different between patient groups before and after the menin­
gococcal C  vaccination campaign. In addition, since 2002,
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treatment of children w ith m eningococcal sepsis at our PICU 
has changed due to the implementation of international gu ide­
lines [8]. A fte r the vaccination campaign, more children were 
treated w ith corticostero ids (18 [9.3% ] before versus 15 
[42 .9% ] after; p  <  0 .001) and more children were m echani­
cally ventilated (128 [51.8% ] before versus 28 [71 .8% ] after; 
p  <  0.05) (Table 3). In addition, year of admission was sign ifi­
cantly correlated w ith the use of dobutam ine (p <  0 .001, rs 
0.262), dopamine (p <  0.001, rs -0.218), norepinephrine (p <  
0.001, rs 0.329), and corticosteroids (p <  0.001, rs 0 .245) but 
not w ith the use of epinephrine. This indicates that during the 
study period the use of dobutamine, norepinephrine, and cor-
Critical Care Vol 11 No 5 Maat et al.
F igu re  4
Num berofchildrenw ithsepsis andpurpura due to  Neisseria meningi­
tidis per year (since 1988), admitted to the paediatric intensive care 
unit of Erasmus MC-Sophia Children's Hospital (Rotterdam, The 
Netherlands).
ticostero ids significantly increased in the treatment of sepsis 
and purpura whereas the use of dopamine significantly 
decreased (Figure 5).
Discussion
In this m onocenter cohort study of 287 children between the 
ages of 0 and 18 years w ith sepsis and purpura, we found that 
younger children had more severe disease and an increased 
risk of case fatality. The CFR of sepsis and purpura has 
improved in recent years despite com parable disease severity 
on admission. Male patients had higher PRISM scores and 
few er PICU-free days. However, the CFR did not differ 
between males and females. Ethnicity did not influence dis­
ease severity and survival. The serogroups of N. m eningitid is  
were not related to severity or survival.
Children w ith sepsis and purpura adm itted to the PICU of the 
Erasmus M C-Sophia Children's Hospital account fo r approxi­
mately 25%  of all paediatric sepsis cases in The Netherlands 
and therefore may provide a representative sample of cases in 
The Netherlands (National PICU registry, unpublished data). In 
addition, Rotterdam covers an area in The Netherlands (that is, 
the southwest of The Netherlands) in which m eningococcal 
disease used to occur frequently.
In this large cohort of paediatric sepsis and purpura, low age 
was significantly associated w ith increased severity of d is­
ease, higher incidence of DIC, and increased CFR. Half of the 
children in our population were younger than 3 years of age. A 
comparison w ith the literature showed that incidence rates 
indeed decline after infancy and then increase again slightly 
during adolescence [1,9,24]. The increased CFR and the 
more severe disease in younger children may result from the 
still-developing immune, coagulation, and stress response
systems in young children and therefore from the relative ina­
bility of young children to induce an effective immune 
response to a high load of m icro-organisms such as N. m en in­
g itid is  [13,19].
The CFR due to sepsis and purpura was 15.7%  over the past 
two decades. This is in accordance w ith other large studies 
reporting CFRs of 10.4%  to 20%  [7,24-26]. It must be noted 
that Jensen and colleagues [7] and Sharip and colleagues
[24] studied m eningococcal disease, not specifica lly paediat­
ric sepsis and purpura.
N. m ening itid is  was the causative organism of sepsis and pur­
pura in the vast majority of cases. Martin and colleagues [27] 
also found that Gram-negative bacteria were the predominant 
causative organisms of sepsis in the US between 1979 and 
1987. In our study, the incidence of disease due to serogroup 
B was much higher than that due to serogroup C. Serogroup 
B N. m ening itid is  was seen more often in younger children 
com pared w ith serogroup C. No differences w ith respect to 
severity of illness scores and CFR were observed between 
serogroups B and C. Erickson and De W als [28] suggested a 
more severe course of serogroup C  infections, indicated by 
increased mortality due to serogroup C  (14% ) com pared w ith 
serogroup B (7%). Spanjaard and colleagues [29] found a 
CFR in m eningococcal sepsis caused by serogroup B of 8.1%  
com pared w ith 7.1%  in serogroup C. However, Erickson and 
De W als [28] studied both m eningitis and sepsis in all culture- 
proven cases of N. m en ing itid is , and Spanjaard and co l­
leagues [29] studied all culture-proven cases including adults 
in The Netherlands, whereas we studied paediatric cases of 
sepsis and purpura.
S ince the implementation of the m eningococcal C  vaccination 
in July 2002, there has not been a fatal case of sepsis and pur­
pura in our PICU. Because severity of disease before and after 
the implementation did not differ between the two groups, the 
increased survival may have resulted from improved treatment 
strategies [8]. International treatm ent guidelines were im ple­
mented at that time, health care workers received additional 
training, and public awareness increased, resulting in a 
decreased patient delay. Furthermore, we observed a change 
in the choice of inotrop ic agents used since 2002. It must be 
noted that the number of children included since 2002  is low. 
However, these observations do warrant further research in a 
prospective study.
G ender was not associated w ith CFR from sepsis and purpura 
although males did have significantly more severe disease, 
based on the PRISM score and fewer PICU-free days, com ­
pared w ith females. Bindl and colleagues [30] found a male- 
to-female ratio of 1.7 in sepsis patients ages 1 week to 8 years 
w ith severe sepsis and septic shock, whereas we observed a 
male-to-female ratio of 1.2. However, in those cases caused 
by N. m eningitid is, which is the major causative organism in
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Table 3
C om parison  o f d isease  characte ris tics  based on se rog roup  o f N e isse ria  m e n in g it id is
Serogroup B
N. meningitidisa
Serogroup C
Total number of children 175 44
Age in years 2.8b B.0b
(0.1 to 17.9) (0.1 to 1B.5)
PRISM score 1B 14
(1 to 37) (1 to 35)
Predicted death rate (%)c 8.9 4.9
(0 to 100) (0 to 100)
Number of children with DIC (%) 128 32
(81) (74)
Number of PICU-free days 24 25
(0 to 28) (0 to 27)
Base excess (mmol/L) -8 -8.0
(-21 to 4.4) (-28 to 3)
Lactate (mmol/L) 4.2 3.5
Geometric mean, 95% CI 3.8 to 4.B 2.9 to 4.2
C-reactive protein (mg/L) 82d 128d
(B to 287) (20 to 32B)
Fibrinogen (g/L) 2.4 2.8
(0.2 to B.8) (0.3 to B.B)
Platelet count (x103/^L) 110 113
(15 to 475) (13 to 336)
Leukocytes (x103/^L) 8.8e 12.2e
Geometric mean, 95% CI 7.B to 10.1 9.9 to 15.0
Glucose (mmol/L) 5.9 B.2
Geometric mean, 95% CI 5.4 to B.5 5.5 to B.9
aResults represent median (min-max) unless stated otherwise. bp <  0.001. cPredicted death rate was based on the Rotterdam score. dp <  0.01. ep 
<  0.05. CI, confidence interval; DIC, disseminated intravascular coagulation; PICU, paediatric intensive care unit; PRISM, Paediatric Risk of 
Mortality.
our study, males and females were represented equally among 
non-survivors. W atson and colleagues [26] and Martin and 
colleagues [27] also found a predisposition fo r male gender in 
sepsis, but they did not specify the male-to-female ratio in sep­
sis caused by N. m eningitid is.
Due to the small number of children in the different ethnic 
groups, we may not have been able to detect differences 
between the different ethnic groups w ith respect to severity or 
case fatality of sepsis and purpura. In addition, during the 18- 
year study period, the dynamics of the Dutch population 
(especially in Rotterdam) underwent changes, which may not 
be reflected in this study. Rosenstein and colleagues [1] p ro­
posed a predisposition for sepsis in children of African 
descent. Sharip and colleagues [24] found an age-adjusted 
increased risk of case fatality in individuals of African descent 
compared w ith Caucasians and other ethnic groups.
A  possib le limitation of our study may be that the serotypes of 
N. m eningitid is  were not determ ined in all children w ith menin­
gococcal sepsis. Due to the rapidly progressive nature of this 
disease, it is possible that we did not include a number of the 
most severe cases because of case fatality before admission 
or referral to the Erasmus M C-Sophia Children's Hospital. On 
the other hand, the fact that only children w ith sepsis and pur­
pura adm itted to the PICU were included may have resulted in
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Table  4
C om parison  o f d isease cha racte ris tics  be tw een ch ild ren  w ith  seps is  and purpura  be fo re  and a fte r th e  na tiona l m eningococca l C 
vacc ina tion  cam paign (July 2002)
Before meningococcal C vaccinationa After meningococcal C vaccinationa
Total number of children (%) 248 39
(8B.4) (13.6)
Case fatality (%) 45b 0b
(18.1) (0)
Age in years 3.2 2.5
(0.1 to 17.9) (0.3 to 13.1)
Number of children with DIC (%) 186c 20c
(79.5) (62.5)
Number of PICU-free days 24c 25c
(0 to 28) (0 to 27)
PRISM score 15 20
(1 to 44) (2 to 37)
Predicted death rate (%)d 5.B 8.1
(0 to 100) (0 to 100)
Base excess (mmol/L) -7.7 -8
(-28 to 4.4) (-18 to -2)
Lactate (mmol/L) 4.1 4.0
Geometric mean, 95%  CI 3.8 to 4.4 3.3 to 4.8
C-reactive protein (mg/L) 93 84
(B to 32B) (25 to 334)
Fibrinogen (g/L) 2.5 3.2
(0.2 to B.8) (0.3 to 6.4)
Platelet count (x103/^L) 110 135
(13 to 475) (25 to 227)
Leukocytes (x103/^L) 8.9 12.1
Geometric mean, 95%  CI 7.9 to 10.0 9.4 to 15.6
Glucose (mmol/L) 5.7c 7.2c
Geometric mean, 95%  CI 5.3 to 6.2 6.2 to 8.2
aResults represent median (min-max) unless stated otherwise. bp <  0.01. cp <  0.05. dPredicted death rate was based on the Rotterdam score. CI, 
confidence interval; DIC, disseminated intravascular coagulation; PICU, paediatric intensive care unit; PRISM, Paediatric Risk of Mortality.
a skewed representation of all children w ith sepsis and 
purpura (that is, children w ith relatively mild disease admitted 
to a general ward).
Conclusion
The CFR in this study was 15.7%. Age was the most important 
p red ic tor of severity and case fatality of sepsis and purpura. 
Male gender was associated w ith higher PRISM scores and 
few er PICU-free days, but no differences in CFR were seen. 
N. m eningitid is  was the causative organism in the vast majority
of cases. No differences between N. m eningitid is  serogroups 
B and C  w ith respect to disease severity scores and case 
fatality were observed. Ethnicity was not associated w ith the 
course of sepsis and purpura.
In future studies investigating effects on severity and survival 
of sepsis and purpura, age and gender should be taken into 
account. The possible effect of the change in choice of 
inotrop ic agents warrants further investigation. Also, other 
possible differences between male and female patients w ith
Page 8  of 10
(page number not for citation purposes)
Ava ilab le  on line  http://ccf0rum.c0m/c0ntent/l 1/5/R112
F igure  5
60
50
û O O ï O « —i r s i r f l * ^ - L r t k 0 r ~ ' 0 0 < T î O r H r M f Y > » d ' L r t ^ û  
c o c o d < r . < j i C T i c r . c i c r i C i c r i < j i O O O O O O O  
u ' i o - . c ' i o - « c - > c ' i c r 1 c r > a - i c - i c - . c ' > o o o o o o o
i—i i —i i —I « —i i —l i —l i —l i —I « —l i —I « —i t —( c ' J r ' J r ' j r ' j r N r M r ' J
Year of admission
■ Use o f Dobutamine ■ Use of Dopamine ■ Use o f Norepinephrine
■ Usé o f Epinephrine ■ N o useo f inotropics
Use of inotropic agents during the study period 1988 to 2006. Some 
patients received more than one inotropic agent. Therefore, the number 
of patients in this figure exceeds the number of patients in this study (N 
=  287).
sepsis should be investigated. W ith  the changing demography 
in The Netherlands (especially in the Rotterdam area), differ­
ences between ethnic groups require further examination.
Key m essages
• Mortality of children w ith sepsis and purpura improved 
substantially from 1988 to 2006. A  possible explanation 
is an improvement in supportive treatment.
• Younger children (below  3 years of age) have a more 
severe disease state and a higher risk of case fatality 
than older children.
• Male patients have a more severe disease according to 
disease severity scoring systems, but this has not led to 
increased mortality in this group of 287 children.
• The major causative organism of sepsis and purpura in 
children is Neisseria m eningitid is. S ince the in troduc­
tion of the vaccination in 2002, N. m ening itid is  sero­
group C  has com pletely vanished as a causative 
organism.
• Serogroup of N. m eningitid is  and ethnicity were not 
associated w ith the course of disease in children w ith 
sepsis and purpura.
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